MISGAV, Israel, May 15, 2012 /PRNewswire/ --
Stimatix GI Ltd., a leading developer of low-profile innovative solutions for colostomy management, announced today that it has completed its FDA registration and device listing for its AOS-C2000™ as part of its commercial distribution plans in the U.S.
Stimatix GI is developing the AOS-C1000™ and the AOS-C2000™ as part of its colostomy product line that provides voluntary bowel evacuation and improves the quality of life for people with a stoma.
In parallel, filing of the AOS-C2000™ in the European Union for obtaining the CE mark is expected shortly. The filing activities are to be followed by post marketing surveillance, aiming at product readiness to market in the EU by the end of the year.
"Accomplishing this achievement on schedule is a major milestone in our vision to set a new standard in stoma care, and to enhance the quality of life for individuals with colostomies," says David Hanuka, CEO of Stimatix GI.
About Stimatix GI Medical Ltd.
Stimatix GI was founded in June 2009 and is a portfolio company of The Trendlines Group's Misgav Venture Accelerator. Stimatix GI develops innovative management devices for people with stoma intended to improve quality of life. The company has recently closed its 2nd funding round led by The Lazarus Israel Opportunities Fund, LLLP. More information at http://www.stimatix-gi.com.
The Trendlines Group (http://www.trendlines.com) establishes, invests in, and develops innovation-based businesses in the medical and agritech fields. Seed-stage investors, Trendlines invests principally through a platform of Israeli government-licensed business accelerators, Misgav Venture Accelerator (http://www.misgav-venture.com) and Mofet Venture Accelerator (http://www.mofet-venture.com). Over the last four years, Trendlines has attracted investments exceeding $140 million.
Dorit Orly, +972-52-2525167
Ofir Shpigel's Media and Public Relations, +972-4-9535030
SOURCE Stimatix GI Ltd